| MeSH term | MeSH ID | Detail |
|---|---|---|
| Mycobacterium Infections, Nontuberculous | D009165 | 8 associated lipids |
| Nail Diseases | D009260 | 2 associated lipids |
| Paronychia | D010304 | 3 associated lipids |
| Duodenal Ulcer | D004381 | 12 associated lipids |
| Dyspnea | D004417 | 10 associated lipids |
| Vascular Diseases | D014652 | 16 associated lipids |
| Heart Defects, Congenital | D006330 | 20 associated lipids |
| Listeriosis | D008088 | 12 associated lipids |
| Connective Tissue Diseases | D003240 | 2 associated lipids |
| Ascites | D001201 | 25 associated lipids |
| Albuminuria | D000419 | 18 associated lipids |
| Anemia | D000740 | 21 associated lipids |
| Osteomalacia | D010018 | 5 associated lipids |
| Tremor | D014202 | 15 associated lipids |
| Pemphigoid, Bullous | D010391 | 8 associated lipids |
| Vasculitis | D014657 | 14 associated lipids |
| Hypothermia | D007035 | 19 associated lipids |
| Parkinson Disease | D010300 | 53 associated lipids |
| Down Syndrome | D004314 | 18 associated lipids |
| Adrenal Insufficiency | D000309 | 3 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Tümgör G et al. | A case of uneventful ABO-incompatible liver transplantation from a deceased donor managed with routine immunosuppressive treatment. | 2014 | Turk J Gastroenterol | pmid:25599790 |
| Dinçkan A et al. | Evaluation of the first 100 liver transplantations. | 2008 | Turk J Gastroenterol | pmid:18386237 |
| Bajetta E et al. | Merkel cell carcinoma after liver transplantation: a case report. | 2007 May-Jun | Tumori | pmid:17679476 |
| Vennarecci G et al. | [Acute liver toxicity of antiretroviral therapy (HAART) after liver transplantation in a patient with HIV-HCV coinfection and associated hepatocarcinoma (HCC)]. | 2003 Jul-Aug | Tumori | pmid:12903579 |
| Sommerer C et al. | Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial. | 2016 | Trials | pmid:26888217 |
| Nashan B et al. | Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial. | 2015 | Trials | pmid:25873064 |
| Snyder SH et al. | Neural actions of immunophilin ligands. | 1998 | Trends Pharmacol. Sci. | pmid:9509898 |
| Liu J | FK506 and ciclosporin: molecular probes for studying intracellular signal transduction. | 1993 | Trends Pharmacol. Sci. | pmid:7692652 |
| Chang JY et al. | FK506 and rapamycin: novel pharmacological probes of the immune response. | 1991 | Trends Pharmacol. Sci. | pmid:1710854 |
| Cardenas ME et al. | Signal-transduction cascades as targets for therapeutic intervention by natural products. | 1998 | Trends Biotechnol. | pmid:9807840 |
| Kunz J and Hall MN | Cyclosporin A, FK506 and rapamycin: more than just immunosuppression. | 1993 | Trends Biochem. Sci. | pmid:7694398 |
| Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Drug levels in PHAs who receive liver transplants. | 2003 Apr-May | TreatmentUpdate | pmid:17216847 | |
| Rosen HR et al. | Significance of early aminotransferase elevation after liver transplantation. | 1998 | Transplantation | pmid:9448146 |
| Connor A et al. | Generic tacrolimus in renal transplantation: trough blood concentration as a surrogate for drug exposure. | 2012 | Transplantation | pmid:23318306 |
| Plock JA et al. | Adipose- and Bone Marrow-Derived Mesenchymal Stem Cells Prolong Graft Survival in Vascularized Composite Allotransplantation. | 2015 | Transplantation | pmid:26102613 |
| Stevens RB et al. | Randomized trial of single-dose versus divided-dose rabbit anti-thymocyte globulin induction in renal transplantation: an interim report. | 2008 | Transplantation | pmid:18497677 |
| Gurk-Turner C et al. | Thymoglobulin dose optimization for induction therapy in high risk kidney transplant recipients. | 2008 | Transplantation | pmid:18497682 |
| Selzner N et al. | Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. | 2009 | Transplantation | pmid:19935376 |
| Rush DN et al. | Factors associated with progression of interstitial fibrosis in renal transplant patients receiving tacrolimus and mycophenolate mofetil. | 2009 | Transplantation | pmid:19935461 |
| Gayowski T et al. | Orthotopic liver transplantation in high-risk patients: risk factors associated with mortality and infectious morbidity. | 1998 | Transplantation | pmid:9500623 |
| Arns W et al. | Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients: A Multicenter, Randomized Trial. | 2017 | Transplantation | pmid:28658202 |
| Kim YI et al. | Stimulation of liver regeneration by pretreatment with azathioprine as well as cyclosporine and FK506. | 1992 | Transplantation | pmid:1373539 |
| Budde K et al. | Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. | 2007 | Transplantation | pmid:17318074 |
| Stifft F et al. | Lower variability in 24-hour exposure during once-daily compared to twice-daily tacrolimus formulation in kidney transplantation. | 2014 | Transplantation | pmid:24686426 |
| Shibutani S et al. | Effects of immunosuppressants on induction of regulatory cells after intratracheal delivery of alloantigen. | 2005 | Transplantation | pmid:15849542 |
| Jain A et al. | Pharmacokinetics of tacrolimus in living donor liver transplant and deceased donor liver transplant recipients. | 2008 | Transplantation | pmid:18347534 |
| Kessler M et al. | A renal allograft recipient with late recurrence of focal and segmental glomerulosclerosis after switching from cyclosporine to tacrolimus. | 1999 | Transplantation | pmid:10071045 |
| Robertsen I et al. | Use of generic tacrolimus in elderly renal transplant recipients: precaution is needed. | 2015 | Transplantation | pmid:25148382 |
| Mueller AR et al. | Neurotoxicity after orthotopic liver transplantation. A comparison between cyclosporine and FK506. | 1994 | Transplantation | pmid:7518974 |
| Hirano Y et al. | The effects of FK506 and cyclosporine on the exocrine function of the rat pancreas. | 1992 | Transplantation | pmid:1279850 |
| di Francesco F et al. | One year follow-up of steroid-free immunosuppression plus everolimus in isolated pancreas transplantation. | 2008 | Transplantation | pmid:18946356 |
| Mahé E et al. | Drug-induced hypersensitivity syndrome associated with primary Epstein-Barr virus and human herpesvirus 6 infections in a child intestinal transplant recipient. | 2004 | Transplantation | pmid:14966435 |
| Paramesh AS et al. | Thrombotic microangiopathy associated with combined sirolimus and tacrolimus immunosuppression after intestinal transplantation. | 2004 | Transplantation | pmid:14724447 |
| Boillot O et al. | Reversal of early acute rejection with increased doses of tacrolimus in liver transplantation: a pilot study. | 1998 | Transplantation | pmid:9825815 |
| Jain AB et al. | Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. | 1998 | Transplantation | pmid:9825817 |
| Opelz G | Comparison of FK506 and cyclosporine. | 1996 | Transplantation | pmid:8830844 |
| Zhao W et al. | Pharmacokinetic interaction between tacrolimus and amlodipine in a renal transplant child. | 2012 | Transplantation | pmid:22450597 |
| Yoshimura N et al. | Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. I. Inhibition of expression of alloantigen-activated suppressor cells, as well as induction of alloreactivity. | 1989 | Transplantation | pmid:2465592 |
| Yoshimura N et al. | Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. II. Inhibition of the production of IL-2 and gamma-IFN, but not B cell-stimulating factor 2. | 1989 | Transplantation | pmid:2465593 |
| Ciancio G et al. | A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. | 2005 | Transplantation | pmid:16123718 |
| Ochiai T et al. | Effects of combination treatment with FK506 and cyclosporine on survival time and vascular changes in renal-allograft-recipient dogs. | 1989 | Transplantation | pmid:2474209 |
| Hariharan S | Case 2: strategies to minimize the use of calcineurin inhibitors (CNIs). | 2002 | Transplantation | pmid:12357988 |
| Wu MJ et al. | Lower variability of tacrolimus trough concentration after conversion from prograf to advagraf in stable kidney transplant recipients. | 2011 | Transplantation | pmid:21912349 |
| Stempfle HU et al. | The role of tacrolimus (FK506)-based immunosuppression on bone mineral density and bone turnover after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. | 2002 | Transplantation | pmid:11889427 |
| Aw MM et al. | Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transpland recipients: a preliminary experience. | 2003 | Transplantation | pmid:12660504 |
| Jain A et al. | One thousand consecutive primary liver transplants under tacrolimus immunosuppression: a 17- to 20-year longitudinal follow-up. | 2011 | Transplantation | pmid:21378604 |
| Gruessner RW et al. | Portal donor-specific blood transfusion and mycophenolate mofetil allow steroid avoidance and tacrolimus dose reduction with sustained levels of chimerism in a pig model of intestinal transplantation. | 2004 | Transplantation | pmid:15239611 |
| Macphee IA et al. | Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. | 2005 | Transplantation | pmid:15729180 |
| Margreiter R et al. | A double-hand transplant can be worth the effort! | 2002 | Transplantation | pmid:12134104 |
| Wiesner RH | A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. | 1998 | Transplantation | pmid:9734494 |